Table 2.
Immunophenotype of neoplastic mast cells (MC) in BM sections.
| Expression detected in |
||||
|---|---|---|---|---|
| The patient's BM MC | MC in patients with |
|||
| Antigen/marker | CD | ISMa | ASMa | |
| LFA-2 | CD2 | +/− | − | − |
| IL-2RA | CD25 | −/+ | + | + |
| Ki-1 | CD30 | −/+ | −/+ | + |
| HPCA-1 | CD34 | − | − | − |
| KIT | CD117 | + | + | + |
| CAE | n.c. | + | +/− | +/− |
| MPO | n.c. | − | − | − |
| Chymase | n.c. | − | +/− | − |
| Tryptase | n.c. | + | + | + |
| Ki-67 | n.c. | +/−b | − | − |
Data were obtained by indirect immunohistochemistry using antibodies directed against various leukocyte (differentiation) antigens.
MC, mast cells; BM, bone marrow; ISM, indolent SM; ASM, aggressive SM; IL-2RA, interleukin-2 receptor alpha chain; HPCA-1, human progenitor cell antigen-1; CAE, chloroacetate esterase; MPO, myeloperoxidase; n.c., not yet clustered.
a
Data refer to the published literature and own unpublished observations.
b
As assessed by KIT/Ki-67 double-staining experiments, about 20% of all mast cells were found to stain positive for Ki-67 in this patient.